Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones

被引：48

作者：

Colletti, SL ^{[1
]}

Frie, JL ^{[1
]}

Dixon, EC ^{[1
]}

Singh, SB ^{[1
]}

Choi, BK ^{[1
]}

Scapin, G ^{[1
]}

Fitzgerald, CE ^{[1
]}

Kumar, S ^{[1
]}

Nichols, EA ^{[1
]}

O'Keefe, SJ ^{[1
]}

O'Neill, EA ^{[1
]}

Porter, G ^{[1
]}

Samuel, K ^{[1
]}

Schmatz, DM ^{[1
]}

Schwartz, CD ^{[1
]}

Shoop, WL ^{[1
]}

Thompson, CM ^{[1
]}

Thompson, JE ^{[1
]}

Wang, RX ^{[1
]}

Woods, A ^{[1
]}

Zaller, DM ^{[1
]}

Doherty, JB ^{[1
]}

机构：

[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2003年 / 46卷 / 03期

关键词：

D O I：

10.1021/jm025585h

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Imidazo[1,2-alpha]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.

引用

页码：349 / 352

页数：4

共 24 条

[1]

[Anonymous], [No title captured], Patent No. 9964400

[2]

Bemis GW., 1998, patent, Patent No. [WO9827098, 9827098]

[3] New inhibitors of p38 kinase [J].

Boehm, JC ;

Adams, JL .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37

[4]

Bondeson J, 2001, INT J CLIN PRACT, V55, P211

[5] MAP kinases [J].

Chen, Z ;

Gibson, TB ;

Robinson, F ;

Silvestro, L ;

Pearson, G ;

Xu, BE ;

Wright, A ;

Vanderbilt, C ;

Cobb, MH .

CHEMICAL REVIEWS, 2001, 101 (08) :2449-2476

[6]

CLAIBORN CF, 2001, Patent No. 0122965

[7] Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSBP kinase [J].

Gallagher, TF ;

Seibel, GL ;

Kassis, S ;

Laydon, JT ;

Blumenthal, MJ ;

Lee, JC ;

Lee, D ;

Boehm, JC ;

FierThompson, SM ;

Abt, JW ;

Soreson, ME ;

Smietana, JM ;

Hall, RF ;

Garigipati, RS ;

Bender, PE ;

Erhard, KF ;

Krog, AJ ;

Hofmann, GA ;

Sheldrake, PL ;

McDonnell, PC ;

Kumar, S ;

Young, PR ;

Adams, JL .

BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (01) :49-64

[8]

GILCHRIST TL, 1997, HETEROCYCLIC CHEM, P298

[9] Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial [J].

Heyndrickx, G ;

Renard, M ;

Beil, S ;

Doering, W ;

Kauder, E ;

Klepzig, H ;

Schacherer, C ;

Haass, M ;

Kruger, C ;

Limbourg, P ;

Liomin, E ;

Maisch, B ;

Schartl, M ;

Simon, H ;

Bernink, PJLM ;

Fels, PW ;

Dohmen, HJM ;

Dunselman, PHJM ;

Baselier, MRP ;

Holwerda, NJ ;

Laarman, GJ ;

Leenders, CM ;

vanLeeuwen, K ;

Michels, HR ;

vanderEnt, M ;

Remme, WJ ;

Withagen, AJAM ;

Gundersen, T ;

Otterstad, JE ;

Froland, G ;

Pedersen, TR ;

Ferreira, JRG ;

deSa, EP ;

SeabraGomes, R ;

Gil, V ;

Abdon, NJ ;

Jonsson, J ;

Lubsen, J .

HEART, 1996, 76 (03) :223-231

[10] Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 delta [J].

Jiang, Y ;

Gram, H ;

Zhao, M ;

New, LG ;

Gu, J ;

Feng, LL ;

DiPadova, F ;

Ulevitch, RJ ;

Han, JH .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (48) :30122-30128

← 1 2 3 →